GO-Gd-DTPA Complex for MRI Contrast Agent Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional MRI contrast agents face issues with short half-life, cellular toxicity, and low dispersibility, leading to coagulation in the body when injected, which limits their effectiveness in early disease diagnosis.
Innovation Solution
A GO-Gd-DTPA complex is formed by bonding graphene oxide with gadopentetic acid using an ester bond, enhancing dispersibility and stability, and a method involving dissolution in an organic solvent, activation with DCC and DMAP, and filtration to produce a stable MRI contrast agent.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional MRI contrast agents (transition metal ions) are used, then imaging sensitivity is improved, but toxicity increases and half-life shortens
Solution Approach 1:
The patent creates a composite structure by bonding gadopentetic acid (Gd-DTPA) to graphene oxide (GO) through ester bonds, forming a GO-Gd-DTPA complex. This composite material combines the high imaging sensitivity of gadolinium ions with the biocompatibility and stability of graphene oxide, resolving the contradiction between sensitivity and toxicity.
2Reliability
If conventional MRI contrast agents are used, then imaging function is achieved, but dispersibility decreases leading to coagulation in the body
Solution Approach 1:
By forming a composite of Gd-DTPA bonded to graphene oxide, the patent achieves both imaging function and high dispersibility. The graphene oxide component provides excellent dispersibility in physiological environments, preventing coagulation while maintaining the contrast agent's imaging functionality.
3Weight of moving object
If transition metal ions are used as contrast agents, then molecular weight is reduced for easier distribution, but toxicity increases significantly
Solution Approach 1:
The patent combines low molecular weight gadopentetic acid with graphene oxide to create a composite that maintains easy distribution characteristics while the graphene oxide component reduces toxicity through its biocompatible nature and ability to sequester the metal ions.
4Object-affected harmful factors
If gadolinium ions are converted to complexes with biocompatible polymers, then toxicity is reduced, but half-life remains short
Solution Approach 1:
The graphene oxide-Gd-DTPA composite provides both reduced toxicity and extended half-life. The stable ester bond connection and the unique properties of graphene oxide create a complex with improved circulation time and stability in the body, overcoming the short half-life limitation of conventional polymer complexes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The GO-Gd-DTPA complex demonstrates high dispersibility and reduced toxicity, allowing it to remain stable in the body, making it suitable for effective use as an MRI contrast agent with potential for large-scale, cost-effective production.
Implementation Method 1
GO-Gd-DTPA complex, which is formed by an ester bond of graphene oxide (GO) and gadopentetic acid (Gd-DTPA)
Implementation Method 2
the stability of which is improved because it has high dispersibility compared to conventional MRI contrast agents
Data Source
AI summary
Disclosed herein is a GO-Gd-DTPA (gadolinium-diethylenetriamine pentaacetic-graphene oxide) complex, which is formed by an ester bond of graphene oxide (GO) and gadopentetic acid (Gd-DTPA). Since the GO-Gd-DTPA can stably exist in the body because it has high stability in water, it is expected that it can be effectively used as an MRI contrast agent.